$8.17
0.55% yesterday
NYSE, Sep 22, 10:12 pm CET
ISIN
US29089Q1058
Symbol
EBS

Emergent Biosolutions Inc Stock price

$8.18
-1.05 11.38% 1M
+2.45 42.76% 6M
-1.38 14.44% YTD
+2.12 34.98% 1Y
-12.96 61.31% 3Y
-92.57 91.88% 5Y
-20.56 71.54% 10Y
-2.87 25.97% 20Y
NYSE, Closing price Mon, Sep 22 2025
-0.03 0.37%
ISIN
US29089Q1058
Symbol
EBS
Industry

Key metrics

Basic
Market capitalization
$436.4m
Enterprise Value
$836.9m
Net debt
$400.5m
Cash
$267.3m
Shares outstanding
53.7m
Valuation (TTM | estimate)
P/E
3.2 | 6.8
P/S
0.5 | 0.5
EV/Sales
1.0 | 1.1
EV/FCF
5.4
P/B
0.8
Financial Health
Equity Ratio
34.7%
Return on Equity
-39.5%
ROCE
8.4%
ROIC
7.5%
Debt/Equity
1.2
Financials (TTM | estimate)
Revenue
$851.6m | $795.0m
EBITDA
$174.0m | $174.9m
EBIT
$108.9m | $90.4m
Net Income
$139.5m | $64.5m
Free Cash Flow
$155.0m
Growth (TTM | estimate)
Revenue
-22.7% | -23.8%
EBITDA
225.0% | 1,166.7%
EBIT
153.3% | 210.9%
Net Income
123.8% | 133.9%
Free Cash Flow
395.2%
Margin (TTM | estimate)
Gross
53.6%
EBITDA
20.4% | 22.0%
EBIT
12.8%
Net
16.4% | 8.1%
Free Cash Flow
18.2%
More
EPS
$2.6
FCF per Share
$2.9
Short interest
16.5%
Employees
900
Rev per Employee
$1.2m
Show more

Is Emergent Biosolutions Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Emergent Biosolutions Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

5x Buy
71%
1x Hold
14%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

Buy
71%
Hold
14%
Sell
14%

Financial data from Emergent Biosolutions Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
852 852
23% 23%
100%
- Direct Costs 395 395
51% 51%
46%
457 457
52% 52%
54%
- Selling and Administrative Expenses 233 233
33% 33%
27%
- Research and Development Expense 50 50
46% 46%
6%
174 174
225% 225%
20%
- Depreciation and Amortization 65 65
0% 0%
8%
EBIT (Operating Income) EBIT 109 109
153% 153%
13%
Net Profit 140 140
124% 124%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Emergent Biosolutions Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Emergent Biosolutions Inc Stock News

Neutral
GlobeNewsWire
4 days ago
GAITHERSBURG, Md., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured new purchase orders from an international government partner for a multi-product supply agreement valued at $29 million (USD). The orders span several product offerings within Emergent's medical countermeasures (MCM) business, including countermeasures for smallpox, anthra...
Neutral
GlobeNewsWire
8 days ago
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brinci...
Neutral
GlobeNewsWire
14 days ago
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government.
More Emergent Biosolutions Inc News

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Joseph Papa
Employees 900
Founded 1998
Website emergentbiosolutions.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today